Eflornithine oral - Orbus Therapeutics

Drug Profile

Eflornithine oral - Orbus Therapeutics

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Orbus Therapeutics
  • Class Basic amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Anaplastic astrocytoma

Most Recent Events

  • 26 Sep 2016 Eflornithine oral - Orbus Therapeutics receives Orphan Drug status for Anaplastic astrocytoma in USA
  • 01 Jul 2016 Phase-III clinical trials in Anaplastic astrocytoma (Combination therapy, Second-line or greater) in USA (PO) (NCT02796261)
  • 17 Jun 2016 Eflornithine oral - Orbus Therapeutics receives Orphan Drug status for Anaplastic astrocytoma in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top